47,875
Total Publications
2,816,756
Total Citations
Top Researchers
- Mien‐Chie Hung 99,792 citations • 1530 papers
- Martin Pumera 75,710 citations • 1194 papers
- Bing‐Fang Hwang 70,581 citations • 236 papers
- H. Clifford Lane 70,566 citations • 430 papers
- Chung‐Kang Peng 60,665 citations • 372 papers
- Po‐Ren Hsueh 59,747 citations • 1280 papers
- Shafaqat Ali 53,842 citations • 1060 papers
- Agus Sudaryanto 52,047 citations • 101 papers
- İlhan Öztürk 48,275 citations • 457 papers
- H. M. Srivastava 46,945 citations • 1629 papers
Most Cited Papers
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia 2020 • 2,685 citations
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial 2017 • 2,256 citations
- Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention 2013 • 2,174 citations
- Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study 2011 • 1,914 citations
- A marker for Stevens–Johnson syndrome 2004 • 1,731 citations
- Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis 2012 • 1,373 citations
- Current Mechanistic Concepts in Ischemia and Reperfusion Injury 2018 • 1,301 citations
- HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol 2005 • 1,272 citations
- A survey on security and privacy of federated learning 2020 • 1,264 citations
- Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial 2019 • 1,212 citations